FDA Approves Trilostane for Cushing’s in Dogs

The FDA has recently approved a new drug for the treatment of Cushing's Disease in dogs. According to the FDA, Cushing's Disease, which can be found in humans, dogs, cats, and horses, is a result of the adrenal glands creating too much of the hormone Cortisol. Cortisol is a steroid that helps the body cope with stress and "helps regulate proper body weight, tissue structure, skin condition, and other features of good health. But too much cortisol weakens the immune system, leaving the body vulnerable to other diseases and infections."

More from Volume 7, Issue 10 of the AAHA NEWStat newsletter :

The U.S. Food and Drug Administration approved the drug trilostane on May 11 for treatment of pituitary-dependent and adrenal-dependent hyperadrenocorticism (Cushing’s disease) in dogs.

Trilostane is the second FDA-approved drug (after selegiline) to treat Cushing’s in dogs, but is the only drug which attacks both types of the disease.

Trilostane will be sold under the brand name Vetoryl.